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CAR (constitutive active/androstane receptor) regulates both
the distal enhancer PBREM (phenobarbital-responsive enhancer
module) and the proximal element OARE [OA (okadaic acid)
response element] to synergistically up-regulate the endogenous
CYP2B6 (where CYP is cytochrome P450) gene in HepG2 cells.
In this up-regulation, CAR acts as both a transcription factor
and a co-regulator, directly binding to and enhancing PBREM
upon activation by xenobiotics such as TCPOBOP {1,4-bis-
[2-(3,5-dichloropyridyloxy)]benzene} and indirectly associating
with the OARE in response to OA [Swales, Kakizaki, Yamamoto,
Inoue, Kobayashi and Negishi (2005) J. Biol. Chem. 280, 3458–
3466]. We have now identified the cohesin protein SMC1 (struc-
tural maintenance of chromosomes 1) as a CAR-binding protein
and characterized it as a negative regulator of OARE activity,
thus repressing synergy. Treatment with SMC1 small interfering
RNA augmented the synergistic up-regulation of CYP2B6 expres-
sion 20-fold in HepG2 cells, while transient co-expression of
spliced form of SMC1 abrogated the synergistic activation of a
1.8 kb CYP2B6 promoter. SMC1 indirectly binds to a 19 bp se-
quence (−236/−217) immediately downstream from the OARE
in the CYP2B6 promoter. Both DNA affinity and chromatin
immunoprecipitation assays showed that OA treatment dissociates
SMC1 from the CYP2B6 promoter, reciprocating the indirect
binding of CAR to OARE. These results are consistent with the
conclusion that SMC1 binding represses OARE activity and its
dissociation allows the recruitment of CAR to the OARE, syner-
gizing PBREM activity and the expression of the CYP2B6 gene.
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INTRODUCTION
Orphan nuclear receptors such as CAR (constitutive active/andro-
stane receptor), PXR (pregnane X receptor) and PPARα (peroxi-
some-proliferator-activated receptor α) mediate the xenobiotic-
induced transcription of hepatic genes. This induction can result
in serious health consequences, since those genes encode enzymes
and proteins that are involved in the hepatic metabolisms of
compounds such as therapeutic drugs, bilirubin, bile acids, steroid
hormones, glucose and fatty acids [1–5]. CAR was the first to
be characterized as the receptor that is activated by xenobiotics
such as PB (phenobarbital) and the potent PB-type inducer
TCPOBOP {1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene}. The
activated receptor binds to a DR4 motif (direct repeat 4 motif)
within the distal 51-bp PBREM (PB-responsive enhancer module)
and induces the transcription of CYP2B genes (where CYP is
cytochrome P450) [6–8]. The endogenous Cyp2b gene is not
induced by PB in CAR-null mice [9,10]. Moreover, the PBREM-
mutated CYP2B gene is not activated by PB in transgenic mice
[11]. Thus CAR-mediated activation of PBREM is essential for
induction to occur. However, the CAR-mediated activation of
the PBREM and CYP2B promoter by PB-type inducers such as
TCPOBOP in cell-based assays is far less effective compared
with the strong induction of the endogenous Cyp2b gene in
mouse livers in vivo. Therefore the high xenobiotic-inducible
transcription in livers in vivo is not fully explained simply by the
binding of a given receptor to its response element, and requires
additional mechanisms to fill the gap.
Using a HepG2 cell line (called Ym17) that stably expresses
V5-tagged mCAR (mouse CAR), we found that co-treatment with
OA (okadaic acid) synergistically up-regulates the TCPOBOP-
activated human CYP2B promoter to levels similar to that of
Cyp2b induction in vivo. This synergistic up-regulation, called
OA synergy, is regulated by the indirect binding of CAR to the
24 bp element (−256/−233) in the proximal promoter of the hu-
man CYP2B6 gene [12]. The 24 bp element, designated OARE
(OA response element), appears to be unique to the CYP2B6
gene, since OA synergy is not observed with the bilirubin UDP-
glucuronosyltransferase, CYP3A7 and superoxide dismutase 3
genes. These three genes are only moderately induced by PB
in livers in vivo. Thus OARE and its activity provide an ex-
cellent model to further decipher the CAR-mediated regulatory
mechanism that is characteristic of the highly inducible CYP2B
gene. In addition, the regulation of OA synergy is independent
of the CAR nuclear translocation, since CAR is spontaneously
accumulated in the nucleus before OA treatment in Ym17 cells.
OA represses the nuclear accumulation of CAR by PB only
in the primary mouse hepatocytes in which CAR is retained in
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the cytoplasm [13]. In the present study, we have now identified
SMC1 (structural maintenance of chromosomes 1) as a regulatory
factor of the CAR-mediated transcription of the CYP2B6
gene.
SMC1, a member of the SMC family, is a constituent of the
cohesin complex [14–18]. DNA damage triggers the activation of
the checkpoint protein kinase ATM (ataxia telangiectasia mutated)
that phosphorylates various proteins, including SMC1, to form
the double-strand break repair complex [18]. In addition to DNA
repair, SMC1 may also be involved in cell-cycle checkpoint
and gene transcription [15,19]. For example, SMC1 regulates
the Cut gene’s transcription in Drosophila development by aug-
menting the interaction between the Wing enhancer and the
Cut gene promoter. SMC1 has not yet been implemented in
the transcriptional regulation of mammalian genes. Moreover,
it has not been explored whether SMC1 can interact with nuclear
receptors and, if it does, what the biological consequence from
this interaction could be. Here, we have studied the cross-talk
mechanism between CAR and SMC1 to regulate the PB-inducible
activation of the human CYP2B6 gene, by focusing on OARE and
OA synergy. First, we identified SMC1 as a CAR-binding protein.
SMC1 indirectly binds to a 19-bp CYP2B6 promoter sequence
immediately downstream of OARE and represses OA synergy
and, upon OA treatment, dissociates from the promoter. The
present study sheds light on the novel molecular mechanism in
which CAR, acting as both a transcription factor and co-regulator,
co-ordinates multiple elements to regulate this single gene.
MATERIALS AND METHODS
Materials
TCPOBOP and N-dodecanoylsarcosine were purchased from
Sigma Chemical Co. (St. Louis, MO, U.S.A.); OA was from
Calbiochem (San Diego, CA, U.S.A.); poly(dI-dC) · (dI-dC) was
from Amersham Biosciences (Piscataway, NJ, U.S.A.). The plas-
mids pGL3-basic and pcDNA3.1-V5-His-TOPO were obtained
from Promega (Madison, WI, U.S.A.) and Invitrogen (Carlsbad,
CA, U.S.A.) respectively. Antibodies were obtained from either
Invitrogen or Novus Biological (Littleton, CO, U.S.A.). Normal
mouse and rabbit IgGs were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA, U.S.A.). ImmunoPure Immobilized
Protein A was purchased from Pierce (Rockford, IL, U.S.A.).
Cloning and plasmids
The 1.8-kb 5′-flanking DNA of the CYP2B6 gene and its dele-
tion mutants were cloned into basic firefly luciferase reporter
plasmid pGL3-basic as described previously [12]. Two different
cDNAs encoding SMC1 were amplified from HepG2 RNAs
and were cloned into the pcDNA3.1-V5-His-TOPO plasmid
(Invitrogen): full-length SMC1 and an SMC1 variant lacking
amino acid residues from positions 313–425 (SMC1313-425). The
following mutants were also constructed in pcDNA3.1-V5-His-
TOPO; pcDNA3.1-N-g (N-terminal globular domain; SMC1,
Met1 to Arg160); pcDNA3.1-N-c (N-terminal coiled coil domain;
SMC1, Ser161 to Leu510); pcDNA3.1-hinge (SMC1, Tyr511 to
Gly655); pcDNA3.1-C-c (C-terminal coiled coil domain; SMC1,
Ala656 to Thr1005); pcDNA3.1-C-g (C-terminal globular domain;
SMC1, Leu1006 to Gln1233); pcDNA3.1-SMC1-NC-del (SMC1
mutant lacking both N- and C-terminal globular domains; SMC1,
Ser161 to Thr1005). The cDNA of SMC1313-425, N-g, N-c and C-
g of SMC1 were also cloned into pGEX4T3 to produce GST
(glutathione S-transferase)-fusion proteins. These constructs were
verified by their sequences. All other plasmids were previously
constructed in this laboratory.
Cell culture
Cells were cultured in MEM (minimal essential medium) sup-
plemented with 10% (v/v) fetal bovine serum and antibiotics
(100 units/ml penicillin and 100 µg/ml streptomycin). The Ym17
cell line was produced previously [12].
Real-time PCR
Preparation of total RNA and the subsequent synthesis of first
strand cDNA were performed using TRIzol® reagent (Invitrogen)
and High Capacity cDNA Archive kit (Applied Biosystems,
Foster City, CA, U.S.A.) respectively. With the resulting cDNA,
real-time PCR was performed to measure CYP2B6 mRNA using
ABI Prism 7700 (Applied Biosystems) as described previously
[12]. Primer and probe sets used for PCR analysis were as
follows: 5′- and 3′-primers respectively, 5′-AAGCGGATTTG-
TCTTGGTGAA-3′, 5′-TGGAGGATGGTGGTGAAGAAG-3′,
and probe 6FAM (6-carboxyfluorescein)-CATCGCCCGTGCG-
GAATTGTTC-TAMRA (6-carboxytetramethylrhodamine). The
amount of CYP2B6 mRNA was normalized by β-actin mRNA
that was measured by using a Pre-Developed Taqman Assay for
human β-actin (Applied Biosystems).
Purification of CAR complex
V5-antibody (250 µg) or normal mouse IgG (250 µg) were con-
jugated with Protein G resin (100 µl) using ImmunoPure Pro-
tein G IgG Orientation kit (Pierce). After being treated with
TCPOBOP for 1 h at 37 ◦C, Ym17 cells were harvested from
700 confluent 145 cm2 dishes, from which nuclear extracts and
250 mg of nuclear proteins were prepared as previously described
[20]. Nuclear extracts were diluted with the same volume of buffer
A [20 mM Tris/HCl, pH 7.5, containing 0.3 M NaCl, 0.2% NP40
(Nonidet P40) and 10% (v/v) glycerol] and were shaken with V5-
antibody–Protein G for 2 h. The resin was sequentially eluted with
buffer A and 20 mM Hepes buffer (pH 7.5) containing 0.2% N-
dodecanoylsarcosine and 0.1 M glycine/HCl (pH 2.8). Finally, the
remaining proteins were eluted with 0.1 M glycine/HCl (pH 2.8)
containing 0.1% Triton X-100. All procedures were carried out
at 4 ◦C. Purified proteins were freeze-dried, separated on 4–
12% NuPage Bis-Tris/polyacrylamide gel, stained with CBB
(Coomassie Brilliant Blue) R-250 and subjected to MS analysis.
MS analysis
The MS identification of in-gel digested proteins has been
described in detail elsewhere [21–23]. Briefly, individual gel
bands were excised and subjected to trypsin proteolysis using a
ProGest automated digester (Genomic Solutions). The extracted
peptides were analysed on a MALDI–TOF/TOF (matrix-
assisted laser-desorption ionization–tandem time-of-flight) mass
spectrometer (Voyager 4700) from Applied Biosystems. Data
were internally calibrated with trypsin autoproteolysis peaks
and submitted to the MASCOT database search engine (Matrix
Science) for protein identification by peptide mass ‘fingerprinting’
and sequence tag approaches.
Western blot
Proteins were separated on a 4–12 % NuPage Bis-Tris/poly-
acrylamide gel and transferred on to Immobilon-P membrane
(Millipore, Bedford MA, U.S.A.). Subsequently, these mem-
branes were incubated for 1 h at 25 ◦C or overnight at 4 ◦C with
anti-SMC1, anti-SMC3, anti-V5 or anti-V5–HRP (horseradish
peroxidase) (1:5000 dilutions) in 5 % (w/v) non-fat milk in Tris-
buffered saline/0.2% (v/v) Tween 20. Subsequently, they were
incubated with HRP-conjugated anti-rabbit or anti-mouse IgG
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(1:5000 dilution; Santa Cruz Biotechnology). Protein bands were
visualized by ECL® Plus Western blotting detection (Amersham
Biosciences).
GST pull-down assays
Recombinant GST and GST-fusion proteins were expressed
from their pGEX4T3 plasmids (Amersham Biosciences) in
Escherichia coli BL21 (DE3) cells and were purified by standard
procedures. pcDNA3.1-SMC1, pcDNA3.1-SMC1313-425,
pcDNA3.1-SMC1-NC-del, pcDNA3.1-N-g, pcDNA3.1-N-
c, pcDNA3.1-hinge, pcDNA3.1-C-c, pcDNA3.1-C-g, pCR3-
mCAR, pCR3-hCAR, pGEM-hRXR and pcDNA3.1-hGR were
used to produce in vitro translated proteins in TNT® Quick
Coupled Transcription/Translation System (Promega) and
[35S]methionine (Amersham Biosciences). GST or GST-fusion
proteins were immobilized on glutathione-S-Sepharose beads
and were incubated with 5 µl of an in vitro translated protein in
500 µl of HBST (50 mM Hepes, pH 7.5, 0.1 M NaCl and 0.01 %
Triton X-100) for 30 min at room temperature (25 ◦C). After three
washes in 1 ml of HBST, proteins were eluted in SDS/PAGE
sample buffer (NuPAGE LDS Sample buffer; Invitrogen) at
70 ◦C for 5 min, separated on a 4–12% NuPage Bis-Tris gel
(Invitrogen) and stained with CBB. The stained gel was also
subjected to autoradiography.
Transfection assays
Ym17 cells in a 24-well plate were transfected with a given
pGL3basic luciferase reporter plasmid (0.2 µg/well) and phRL-
TK plasmid (Promega) (0.1 µg/well) by LipofectamineTM 2000
(Invitrogen) according to the manufacturer’s instructions, with
an additional co-transfection of 0.2 µg/well pcDNA3.1 bearing
SMC1 or each of its mutants or pcDNA3.1. After 24 h, the cells
were subjected to treatment with chemicals (DMSO, TCPOBOP,
OA or TCPOBOP plus OA) for an additional 48 h. Luciferase
activity was measured using the Dual-Luciferase reporter assay
system (Promega).
siRNA (small interfering RNA) expression
siRNAs were obtained from Dharmacon Research (Lafayette, CO,
U.S.A.): SMC1 5′-GCAAUGCCCUUGUCUGUGA-3′, 5′-UC-
ACAGACAAGGGCAUUGCUU-3′. 100 pmol of SMC1 siRNA
or control siRNA (siCONTROL Non-Targeting siRNA no. 1) pre-
pared by Dharmacon Research was co-transfected with −1.8-kb-
CYP2B6-pGL3basic and hpRL-TK into Ym17 cells in each well
of 24-well plates. After 24 h, the cells were treated with chemicals.
Reduction of SMC1 protein was confirmed by Western-blot
analysis.
DNA affinity chromatography
Dynabeads® M-280 streptavidin (Dynal ASA, Oslo, Norway)
was conjugated with multiple copies of wild-type −257/−217-
bp oligonucleotide or −257/−217-bp with the −252/−237
region mutated −257/−217mut [12] as described previously
[7]. DNA beads were equilibrated with 25 mM Hepes (pH 7.6)
containing 0.1 M NaCl, 10% glycerol, 0.5 mM EDTA, 0.5 mM
DTT (dithiothreitol), 0.5% NP40, 20 µg/ml herring testes carrier
DNA and 10 µg/ml poly(dI-dC) · (dI-dC) and were shaken with
200 µl of nuclear extract (1 mg of protein/ml), then washed
with equilibrating buffer three times and then with equilibrating
buffer containing 0.3 M NaCl. Subsequently, bound proteins were
eluted by increasing the NaCl concentration to 0.5 M.
Immunoprecipitation
The DNA beads were shaken with nuclear extracts and washed
with equilibrating buffer (flow-through). The bound proteins
were washed with the equilibration buffer containing 0.3 M
NaCl (wash) and eluted by increasing NaCl concentration to
0.5 M (eluate). Anti-SMC1 antibody (1 µg) or normal rabbit IgG
(1 µg) was mixed with these fractions at 4 ◦C. After 12–16 h,
20 µl of 50% slurry of Protein A–agarose was added to this
incubation mixture and was incubated for an additional 1 h at
4 ◦C. Agarose was washed by repeated centrifugations in 1 ml
of the equilibrating solution for DNA affinity chromatography.
Proteins were directly eluted from the agarose in SDS/PAGE
sample buffer by incubation at 70 ◦C for 5 min, separated on a
4–12% NuPage Bis-Tris/polyacrylamide gel and subjected to
Western-blot analysis.
ChIP (chromatin immunoprecipitation) assay
Approx. 1.5 × 107 cells were harvested by trypsinization, for
assays using ChIP assay kit (Upstate Biotechnologies,
Charlottesville, VA, U.S.A.), at 48 h after treatment with DMSO
or TCPOBOP plus OA. Harvested cells were suspended in
10 ml of serum-free MEM and fixed by adding 270 µl of
formaldehyde and gently shaking at room temperature for 30 min.
A one-twentieth volume of 2.5 M glycine was added to fixed
cell suspension with an additional 5 min shaking at room
temperature. Fixed cells were collected by centrifugation, washed
with cold PBS (pH 7.5), homogenized in 1 ml of 10 mM Hepes
(pH 7.5) containing 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT
and 0.3% NP40 supplemented with CompleteTM Mini (Roche
Diagnostics, Mannheim, Germany) and collected by centri-
fugation. Washed cells were precipitated and resuspended in
500 µl of SDS lysis buffer (ChIP assay kit) supplemented with
CompleteTM Mini protease inhibitors for sonication by Misonix
MicrosonTM XL 2000 ultrasonic cell disrupter. The sonicated
material was centrifuged at 14000 g for 15 min and diluted with
dilution buffer (ChIP assay kit) 10 times. The diluted lysates were
pre-cleared by incubating with 200 µl of Protein A for 3 h at 4 ◦C.
Cleared lysates (1 ml) were subjected to overnight incubation with
either 5 µg of antibody, normal rabbit IgG or no antibody at 4 ◦C.
Immunocomplexes were precipitated by adding 30 µl of Protein A
for 1 h at 4 ◦C with shaking, washed with buffers included in ChIP
assay kit, eluted and de-cross-linked in 500 µl of elution buffer
(0.1 M NaHCO3, 1% SDS and 0.3 M NaCl) for 4 h at 65 ◦C.
After protease digestion, DNA was purified using QIAquick PCR
Purification kit (Qiagen, Valencia, CA, U.S.A.) and suspended in
40 µl of elution buffer. Input chromatin and immunoprecipitated
DNA were PCR-amplified in 10 µl of reaction mixture with
LA (long and accurate) Taq polymerase (Takara, Otsu Shiga,
Japan), resolved on a 1.5 % (w/v) agarose gel and visualized
by ethidium bromide staining. The primer sequences that were
designed to amplify the −338 and −99 region were used for
analysis: Forward (5′-AGACAAACAGACAAAGCTAA-3′) and
Reverse (5′-AGGAGCATTAGCTTAGAAAA-3′).
RESULTS
Purification and identification of SMC1
Ym17 cells express mCAR–V5-fusion protein [12]. The nuclear
proteins prepared from TCPOBOP-treated Ym17 cells were
incubated with V5 antibody–agarose or normal IgG–agarose. The
proteins that bound to the agarose were eluted with a pH 2.8
buffer containing detergent. CAR was enriched in the eluate
from V5 antibody–agarose but not from the normal IgG–agarose
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Figure 1 Purification of CAR complex from nuclear extracts of Ym17 cells
Protein complexes were purified using a V5 antibody (α-V5) column or normal mouse
IgG (nmIgG) column. The nuclear extract (NE), flow-through (FT) fraction and the fraction
eluted with 0.2 M glycine/HCl (pH 2.8) containing 0.1 % Triton X-100 (E) were applied to
an SDS/4–12 % polyacrylamide gel. (A) Western-blot analysis was performed using the V5
antibody to detect mCAR. (B) The protein band of mCAR was visualized by silver staining. (C)
The band corresponding to SMC1 was stained by CBB.
(Figures 1A and 1B). After being separated side-by-side on an
SDS/polyacrylamide gel, all CBB-stained bands on the gel were
subjected to MS analysis. One such band that appeared above
the 116.3 kDa marker was only present in the eluate from the V5
antibody–agarose (Figure 1C). Subsequent MS analysis identified
this protein as SMC1, while no peptide of SMC1 was detected
from the corresponding area of gel after electrophoresis of the
proteins eluted from the normal IgG–agarose. A co-purification
of SMC1 with CAR indicated that SMC1 is a constituent of the
nuclear CAR complex in Ym17 cells.
CAR binding region of SMC1
Direct interaction between CAR and SMC1 was analysed by
GST pull-down assays. The SMC1 molecule can be divided into
the following subdomains: N- and C-terminal globular domains,
N- and C-terminal coiled coil regions and a hinge region that
connects the two coils (Figure 2A). Both the full-length SMC1
and SMC1313-425 exhibited binding to CAR (Figure 2B). Since the
113-residue deletion resides in the N-terminal coiled coil region,
CAR did not appear to bind to this coiled coil region. Therefore
the other subdomains (globular domains, coils and hinge) were
in vitro translated separately in the presence of 35S-labelled
methionine to test their binding to CAR. In binding assays,
GST–CAR-fusion protein pulled down both N- and C-terminal
globular domains, but neither coiled coil domains (Figure 2B).
The assay was also performed using GST-fusion proteins of the
SMC1313-425, globular domains and in vitro translated mCAR,
substantiating the observation that CAR binds preferentially to
the globular domains at both termini of the SMC1 molecule (Fig-
ure 2C). Examination of the binding of the hinge region was
prevented due to experimental limitations, such as the hinge
region not being sufficiently labelled by in vitro translation since
it contains only one methionine residue. However, the SMC1-
NC-del was not capable of binding to CAR, suggesting that the
hinge region is not required for CAR binding. Like mCAR, hCAR
(human CAR) and GR (glucocorticoid receptor) bound to globular
domains of SMC1 and SMC1313-425 but human RXR (retinoid X
receptor) did not (Figure 2C).
SMC1 as a repressor of the promoter activity
Treatment with OA synergistically up-regulated CAR-mediated
induction of the endogenous CYP2B6 gene by TCPOBOP in
Ym17 cells, having led us to elucidate the phenomenon called
OA synergy [12]. To investigate the role for SMC1 in the
synergistic up-regulation of CYP2B6 gene, siRNA was employed
to specifically knock down SMC1 in Ym17 cells. Western-blot
analysis showed a nearly 70% decrease in SMC1, but not SMC3
or mCAR, in the SMC1 siRNA-transfected Ym17 cells (Figure 3).
While the rate of OA synergy (i.e. fold induction of CYP2B6
mRNA by the co-treatment divided by the sum of those by
single treatments with TCPOBOP and OA) was 30-fold in control
Ym17 cells, OA synergy was increased up to 300-fold in the
SMC1 siRNA-transfected Ym17 cells (Figure 4A). Thus SMC1-
knocked-down Ym17 cells exhibited OA synergy 10-fold greater
than the cells transfected with control siRNA. Both TCPOBOP-
and OA-dependent inductions were also increased in SMC1-
knocked-down cells (3-fold for TCPOBOP, 4-fold for OA; inset
of Figure 4A). A similar effect of SMC1 siRNA was also observed
with transcription activity of the −1.8 kb CYP2B6 promoter-
luciferase reporter gene; OA synergy was double in SMC1 siRNA-
transfected Ym17 cells compared with that observed in cells
transfected with control siRNA (Figure 4B). A much stronger
effect of SMC1 siRNA was observed with the expression of
endogenous CYP2B6 gene, which may suggest that chromatin
structure may be involved in SMC1-mediated regulation.
Given the fact that the SMC1 knockdown augmented the
synergistic activation of −1.8 kb CYP2B6 promoter, we co-
expressed SMC1 with the same promoter in Ym17 cells to in-
vestigate whether SMC1 overexpression repressed the promoter.
The SMC1313-425 variant was found to effectively repress both the
OA-dependent activation as well as OA-dependent synergistic
activation of the −1.8 kb CYP2B6 promoter, while the full-
length SMC1 did not repress either activation (Figure 5). Since
the deletion resides within the N-terminal coiled coil region, the
different ability of SMC1313-425 and full-length SMC1 to repress
the promoter suggested that this coil region may be responsible
for the repression. Therefore various deletion mutants of SMC1
were constructed based on these structural characteristics
and were tested for their ability to repress the CYP2B6 promoter.
Only the N-terminal coiled coil region (N-c) effectively repressed
the OA-dependent activation as well as OA synergy of the
−1.8 kb CYP2B6 promoter (Figure 5). No other subdomains
(i.e. C-terminal coiled coil, hinge domains and N- and C-
terminal globular domains) repressed the promoter activity. This
dominant-negative function of the N-terminal coiled coil was
further confirmed by using the SMC1-NC-del mutant (Ser161–
Thr1005) that contained the coiled coil regions but lacked both
globular domains, which also repressed the promoter activity. A
similar experiment was performed using V5-His-tagged SMC1,
SMC1313-425 and SMC1-NC-del to confirm the expression level
of these proteins in transfected cells (see Supplementary data at
http://www.BiochemJ.org/bj/398/bj3980125add.htm).
OA synergy occurs when both the PBREM and the −307-bp
promoter are present and the OA response activity resides within
the −307-bp promoter [12]. To delineate the promoter region
responsible for the SMC1-dependent repression of OA synergy,
various internal deletions within the −307-bp proximal promoter
were constructed in the context of the −1.8-kb CYP2B6 pro-
moter. These deletion constructs were co-expressed with the
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Figure 2 GST pull-down assay to identify the CAR-binding region of SMC1
(A) Schematic diagram of the subdomains of the SMC1 and SMC1313-425 molecule. N-g denotes N-terminal globular domain; N-c, N-terminal coiled coil domain; hinge, hinge domain; C-c,
C-terminal coiled coil domain; C-g, C-terminal globular domain; NC-del, SMC1-NC-del. Numbers indicate amino acid residues. (B) GST and GST–mCAR were immobilized on glutathione–Sepharose
beads and were incubated with in vitro translated 35S-labelled full-length or mutants of SMC1. Bound proteins were eluted and analysed by SDS/PAGE (4–12 % gel) as described in the Materials
and methods section. (C) GST, GST–SMC1313-425 (SMC1) and GST–SMC1 subdomains (N-g, N-c or C-g) were incubated with in vitro translated mCAR, hCAR, hRXR or hGR for this
assay.
Figure 3 Endogenous SMC1 was depleted by siRNA specific to SMC1
Nuclear extracts prepared from the cells transfected with control siRNA or SMC1 siRNA were
subjected to Western-blot analysis using the SMC1, SMC3 and V5 antibody.
N-terminal coiled coil of SMC1 (SMC1N-c) in Ym17 cells
(Figure 6A). The  − 306/−257,  − 217/−166,  − 165/−125
and − 125/−35 deletion constructs retained the OA synergy in
the TCPOBOP plus OA-treated Ym17 cells (Figure 6A). Two
deletions, namely  − 256/−233 and  − 233/−217, signific-
antly decreased OA synergy, while the residual promoter activity
was still repressed by SMC1N-c. When both − 256/−233 and
 − 233/−217 regions were deleted, the  − 257/−217 con-
struct lost OA synergy. Additionally, the repression by SMC1N-
c also disappeared. Thus the deletion assays delineated the
repression of OA synergy by SMC1N-c to the −257/−217
sequence of the CYP2B6 promoter. Noticeably, the degree of
repression by SMC1N-c in the TCPOBOP plus OA-treated Ym17
cells was correlated with that in the OA-treated, but not in the
TCPOBOP-treated Ym17 cells (Figure 6B). The inhibition by
SMC1N-c was not observed with the PBREM-213 construct,
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Figure 4 Increase of OA synergy by SMC1 siRNA
(A) Ym17 cells were transfected with SMC1 siRNA or control siRNA. The transfected cells were treated with TCPOBOP (250 nM), OA (10 nM) or TCPOBOP plus OA (OA, TC) for 48 h. Total cellular
RNAs were prepared from the treated cells and subjected to real-time reverse transcriptase–PCR of CYP2B6 mRNA. Fold induction was calculated relative to the levels in DMSO-treated cells. The inset
shows enlarged columns for inductions by TCPOBOP and OA. (B) Ym17 cells were transfected with −1.8k-pGL3, phRL-TK plasmids and SMC1 siRNA or control siRNA. The transfected cells were
incubated with TCPOBOP (250 nM), OA (10 nM) or TCPOBOP plus OA for 48 h, harvested and assayed for luciferase activity. Fold induction was calculated by taking the control activity (DMSO) as 1.
Figure 5 Repression of OA synergy by overexpression of SMC1
Various SMC1 subdomains, SMC1313-425 and SMC1-NC-del were co-expressed with −1.8k-
pGL3 and phRL-TK plasmids in Ym17 cells. The transfected cells were treated with TCPOBOP
(250 nM), OA (10 nM) or TCPOBOP plus OA (OA, TC) for 48 h, harvested and assayed for
luciferase activity. Fold induction was calculated by taking the control activity (DMSO) as 1.
underscoring the fact that PBREM is not the direct target of
SMC1-mediated repression. In addition, SMC1N-c did not repress
the CAR-mediated activation of NR1-luciferase reporter gene,
which contains only the DR4 motif (results not shown). SMC1N-
c more effectively repressed OA-dependent activation of the
−1.8-kb CYP2B6 promoter than the activation by TCPOBOP.
Moreover, the OA synergy of the − 257/−217 deletion and
the −307-bp promoter (used as the negative control that was not
regulated by either TCPOBOP or OA) was similarly repressed
by SMC1N-c (Figure 6B). These results suggested that SMC1
represses OA synergy primarily by inhibiting the OA response
activation of the −251/−217 region of the CYP2B6 promoter,
but not TCPOBOP activation of the PBREM.
Protein binding to the −257/−217 sequence
First, gel shift assays were performed to show the binding of
SMC1 to the −257/−217 region using a bacterially expressed
or in vitro translated SMC1 and the 41-bp DNA (−257/−217)
as probe. No band was observed with either full-length, N- or C-
terminal coiled coil in the gel shift assays (results not shown).
Since the recombinant SMC1 did not directly bind to the
−257/−217 region, we employed DNA affinity chromatography
to investigate the possibility that SMC1 binds to the region in
the presence of nuclear proteins. An oligonucleotide of 41 bp
spanning the region −257/−217 or the DNA with mutations in
the −257/−237 region were conjugated to magnetic beads to
produce (−257/−217)-beads and (−257/−217mut)-beads. The
nuclear extracts prepared from Ym17 cells treated with DMSO,
TCPOBOP, OA and TCPOBOP plus OA were incubated with
either (−257/−217)-beads or (−257/−217mut)-beads. After a
wash with low-salt buffer [equilibrating buffer (see the DNA affin-
ity chromatography subsection) containing 0.3 M NaCl], proteins
were eluted with a buffer containing 0.5 M NaCl, separated on
an SDS/polyacrylamide gel and subjected to Western-blot ana-
lysis. SMC1 was present in all eluates from the DMSO- or
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Figure 6 Delineation of the SMC1-dependent repression to the 41-bp region (−257/−217-bp) of the CYP2B6 promoter
Various deletion constructs of the −1.8-kb CYP2B6 promoter, shown in the left panel, were co-transfected with phRL-TK and pcDNA3.1 or pcDNA3.1-SMC1 N-coiled coil (N-c) into Ym17 cells.
The transfected cells were incubated with TCPOBOP (250 nM), OA (10 nM) or TCPOBOP plus OA for 48 h, harvested and assayed for luciferase activity. Fold induction was calculated by taking the
control activity (DMSO) as 1. (B) Fold inhibition of the treatment-dependent promoter activities by the N-coiled coil in the presence or absence of SMC1. The fold inductions in the absence of SMC1
were divided by those in the presence of SMC1. Numbers were calculated by subtracting one from those inhibition rates to make the baseline to zero. The values shown with less than zero indicate
no inhibition.
TCPOBOP-treated nuclear extracts, indicating SMC1 being
included in the protein complex that bound to the −257/−217
region (Figure 7A). SMC1 was only scarcely recovered in the
eluates from the OA-treated or TCPOBOP plus OA-treated Ym17
cells. There was no difference in the SMC1 elution patterns
between (−257/−217) and (−257/−217mut), suggesting that
the −236/−217 region was critical for the binding of SMC1.
Little recovery of SMC1 from DNA affinity chromatography of
the OA-treated sample indicated the association of SMC1 with
the −236/−217 region and its dissociation from the region after
OA treatment.
When the DNA affinity-enriched 0.5 M NaCl fractions were
subjected to Western-blot analysis using V5 antibody, no CAR
was detected in any of these fractions (Figure 7A).
This result was unexpected, since SMC1 was co-purified with
CAR from the nuclear extracts (Figure 1). The presence of an
SMC1–CAR complex was examined in the other fractions of
the nuclear extracts after DNA affinity chromatography with the
(−257/−217)-beads: the fraction that did not bind to the beads
or was washed out with 0.3 M NaCl (flow-through or wash).
Most of the SMC1 was recovered in these two fractions, only
1% of which was obtained in the 0.5 M NaCl eluate. SMC1
antibody co-precipitated CAR from both the flow-through and
0.3 M NaCl wash fractions, indicating that CAR and SMC1
existed as a complex in these unbound fractions to (−257/−217)-
beads (Figure 7B). Thus the SMC1 that did not bind to the
(−257/−217)-beads is present as a complex with CAR, while
the SMC1 bound tightly does not form a complex with CAR. At
least two different forms of SMC1 appear to be present in the nuc-
leus of Ym17 cells: complexes with and without CAR. Only the
SMC1 without CAR appeared to associate with the −236/−217
region.
To further confirm the interaction of SMC1 with the CYP2B6
promoter, ChIP assays were performed. Ym17 cells were treated
with DMSO or TCPOBOP plus OA, from which cross-linked
DNA–protein conjugates were precipitated by SMC1 antibody
to subsequently amplify the −338/−99 bp region of CYP2B6
promoter that contains the −257/−217 region but not PBREM.
Supporting the finding obtained from DNA affinity experiments,
ChIP assays clearly showed that SMC1 decreases its interaction
with the promoter after drug treatment (Figure 7C, αSMC1),
indicating dissociation of SMC1 from the promoter. Background
amplification from the sample of no IgG or normal rabbit IgG
showed no treatment-specific changes, although these levels of
amplification varied from one set of experiments to the next
(Figure 7C). Consistent with previous findings [12] and providing
an excellent evidence for the specificity of ChIP assays, the
interaction of CAR with promoter was greatly enhanced after
co-treatment with OA and TCPOBOP (Figure 7C, αV5). All
results are consistent with the conclusion that SMC1 binds to the
−257/−217 region as a repressor and undergoes OA-dependent
dissociation from the promoter.
DISCUSSION
Our previous work characterized OARE as the positive element
to which CAR indirectly binds and synergizes the TCPOBOP-
dependent PBREM activity following OA treatment [12]. This
CAR-mediated synergistic activation, called OA synergy, of the
CYP2B6 promoter is unique in which one nuclear receptor,
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Figure 7 Treatment-specific interaction of SMC1 with OARRE or CAR
(A) Nuclear extracts were prepared from the Ym17 cells treated with DMSO, TCPOBOP (250 nM),
OA (10 nM) or TCPOBOP plus OA for 48 h and were applied to a DNA affinity column. After
a wash with a buffer containing 0.3 M NaCl, nuclear proteins were eluted by 0.5 M NaCl from
the (−257/−217)-beads or its mutated version (−257/−217mut)-beads and subjected to
Western-blot analysis using SMC1 or V5 antibody. D, T, O and OT denote DMSO, TCPOBOP,
OA and TCPOBOP plus OA respectively. Input is percentage of the proteins that were applied on
columns. (B) Nuclear extracts prepared from DMSO- or OA-treated Ym17 cells were applied
to the (−257/−217)-beads. SMC1 was precipitated from the flow-through (FT) or 0.3 M
NaCl-washed fraction by incubation with 1 µg of SMC1 antibody (αSMC1) or normal rabbit
IgG (nRb IgG). The resulting immunoprecipitates were resolved on 4–12 % polyacrylamide gels
and immunoblotted with the SMC1 or V5 antibody. Input is percentage of the proteins that were
applied on columns. (C) ChIP assays to show the interaction of SMC1 with the promoter. Ym17
cells were treated with DMSO or TCPOBOP plus OA for 48 h, from which assays were performed
for SMC1 antibody (αSMC1), V5 antibody (αV5), normal rabbit IgG (nRb IgG) or no antibody
(no Ab). The purified DNA was amplified by PCR using primers specific to the −257/−217
region (amplicon −338 to −99) and resolved on a 1.5 % agarose gel. Results shown were
generated simultaneously from the same Ym17 cell extracts.
acting as both the transcription factor (i.e. direct binding to
PBREM) and co-activator (i.e. indirect association with OARE),
regulates multiple distinct elements of a single gene. We have
now identified SMC1 as a repressor that negatively regulates
the activity of OARE. In response to OA treatment, the SMC1
complex dissociates from the CYP2B6 promoter, thus enabling
OARE to recruit CAR as the co-activator and up-regulating
synergistically the CYP2B6 promoter.
SMC1 represses OA synergy through its N-terminal coiled coil
in the cell-based transfection assays by binding to the −236/−217
region of CYP2B6 promoter, while its binding to CAR in the
GST pull-down assays is mediated by the N- and/or C-terminal
globular domains. Thus SMC1 spreads these two functions over
the different subdomains, complicating the molecular mech-
anism of how SMC1 represses the OA synergy. Apparently, dele-
tion of the CAR-binding domain may have converted SMC1 into
a dominant active form as a repressor, as suggested by the fact
that N-c and SMC1-NC-del repressed OA synergy in transient
transfection assay. The reason why full-length SMC1 could not
repress OA synergy in the cell-base transfection assays remains
enigmatic. However, the results from SMC1313/425 variant that
could repress OA synergy raises, at least, two possibilities how
SMC1 regulates OA synergy. SMC1 may have to be properly
regulated to confer its repressive activity, and residue(s) within
the 313–425 region may play a regulatory role for SMC1 to
acquire this repressive activity. Although it may be artificial, the
SMC1313/425 may mimic the native form of SMC1 capable of
repressing the synergistic up-regulation of the PBERM enhancer
activity by OARE. Alternatively, SMC1313/425, the naturally
occurring but minor variant of SMC1, is the true form of SMC1
that is actually involved in the OARE repression in HepG2 cells in
vivo. To further decipher the molecular mechanism of how SMC1
represses the OARE, it is important to determine whether the
SMC1313/425 is, in fact, the true repressor in future investigations,
although developing proper antibodies is required to do this
investigation.
SMC1, via the C-terminal globular domain, is known to bind to
A-T-rich sequences or DNA fragments that can form secondary
structures such as cruciforms [24]. Neither the C-terminal nor the
other subdomains bound directly to the CYP2B6 promoter.
The N-terminal globular domain contains an ATP-binding site
and exerts ATPase activity by interacting with the C-terminal
globular domain. This ATPase activity does not appear to be
required, at least, for SMC1 binding to CAR, since the receptor
can independently bind to the N- or C-terminal globular domain.
Although the function of coiled coils is less understood, it is
suggested that this region mediates protein–protein interactions
[25]. The N-terminal coiled coil may interact with an unknown
protein that mediates the indirect binding of SMC1 to cause the
repression of OA synergy. SMC1 dissociates from the CYP2B6
promoter in response to OA treatment, in which OA may directly
alter the phosphorylation of SMC1. ATM kinase phosphorylates
residues Ser957 and Ser966 in the coiled coil region near the C-
terminal globular domain [18]. Intriguingly, while these two
residues were not phosphorylated in the DMSO- or TCPOBOP-
treated Ym17 cells, they were phosphorylated to a certain
level in the OA-treated cells (K. Inoue and M. Negishi, un-
published work). Once the DNA-binding protein that mediates
the interaction of SMC1 with the −236/−217 region is identified
in future investigations, we will be in a better position to answer
this question.
The interaction of SMC1 with CAR is not the first demon-
stration of cross-talk between a nuclear receptor and the DNA
repair protein. For example, ERα (oestrogen receptor α) was
recently reported to bind to a DNA repair enzyme MPG (3-methyl-
adenine DNA glycosylase) [26]. The binding of MPG attenuates
the activity of ERα, down-regulating the transcription of ER
response element-bearing genes. In addition to ERα, our study
showed that GR also binds to SMC1. Thus the cross-talk of SMC1
with nuclear receptors may be a novel mechanism regulating
various receptor-mediated biological functions. CAR activators
such as PB and phenytoin are non-genotoxic carcinogens that
promote HCC (hepatocellular carcinoma) in rodents [27]. The
activation of CAR was recently found to be an essential factor
in HCC promotion, as indicated by the fact that PB does not
promote HCC in the diethylnitrosamine-treated CAR-null mice
[28]. Not only PB and phenytoin, but also the other numerous
non-genotoxic carcinogens are, in fact, activators/ligands of the
so-called xeno-sensing nuclear receptors including CAR, the PXR
and PPARα. The interaction of CAR with SMC1 may provide an
experimental model to examine if CAR, or other nuclear receptors,
can modulate the activities of SMC1 such as DNA repair, thus
opening a new area of biological research into the cross-talk
between nuclear receptors and cohesin proteins.
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